期刊文献+

左西孟旦治疗失代偿性心力衰竭患者的临床疗效观察 被引量:9

The clinical effects of levosimendan in treatment of decompensated heart failure
下载PDF
导出
摘要 目的探讨左西孟旦治疗失代偿性心力衰竭患者的临床效果。方法 70例失代偿性心衰患者随机分为对照组与观察组各35例。两组均予基础治疗,对照组在此基础上给予盐酸多巴酚丁胺治疗,观察组予左西孟旦治疗。比较两组的疗效、治疗前后B型脑钠肽(BNP)、左室射血分数(LVEF)、每搏心输出量(SVI)及不良反应。结果对照组临床治疗总有效率68.57%(24/35),观察组94.29%(33/35)(P<0.05);观察组治疗后BNP、LVEF及SVI较对照组有显著性差异(P<0.05);对照组不良反应发生率为17.14%(6/35),观察组为5.71%(2/35),两组比较差异显著(P<0.05)。结论左西孟旦治疗失代偿性心力衰竭患者的临床效果显著,安全性高,应在临床上加以推广。 Objective To investigate the clinical effects of levosimendan in treatment of decompensated heart failure. Methods Seventy cases were randomly divided into control group and observation group, 35 cases in each group. Both groups were given basic treatment, the control group received dobutamine hydrochloride, the observation group was treated with levosimendan treatment. Clinical efficacy, BNP, LVEF, SVI of:before and after the treatment and adverse reactions were compared. Results The clinical total effective rate of control ~group was 68.57%(24/35), and that of ob- servation group was 94.29%(33/35)(P 〈 0.05); BNP, LVEF and SVI of observation group were compared with the control group, the difference were statistically significant(P 〈 0.05); Incidence of adverse reactions of control group was 17.14% (6/35), and that of the observation group was 5.71%(2/35)(P 〈 0.05). Conclusion The clinical effect of levosimendan in treatment of decompensated heart failure is exact, safe, and should be the promotion and popularization.
出处 《中国现代医生》 2014年第9期52-53,56,共3页 China Modern Doctor
关键词 左西孟旦 失代偿性心衰 不良反应 Levosimendan Decompensated heart failure Adverse reactions
  • 相关文献

参考文献11

二级参考文献75

共引文献215

同被引文献79

  • 1Dec GW. Acute decompensated heart failure: the shrinking role of inotropic therapy[J]. J Am Coll Cardiol,2005,46 ( 1 ) : 65 - 67.
  • 2Cleland JG, Ghosh J, Freemantle N, et al. Clinical trial- supdate and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINA-MIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardi- ac resynchronisation therapy in heart failure [ J ]. Eur J Heart Fail, 2004,6 (4) : 501 - 508.
  • 3Toller WG,Stranz C. Levosimendan, a new inotropic and vas- odilator agent [J]. Anesthesiology ,2006,104 (3) :556 - 569.
  • 4McMurray JJ, Pfeffer MA. Heart failure [J]. Lancet, 2005, 365(9474) : 1877 - 1889.
  • 5Follath F. Newer treatments for deeompensated heart failure: focus on levosimendan [ J ]. Drug Des Devel Ther, 2009,3 : 73 - 78.
  • 6Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes [ J ]. Am J Cardiol,2005,96(6A) :68G-73C.
  • 7Cohen-Solal A,Logeart D, Huang B, et al. Lowered B-type natriuretie peptide in response to levosimendan or dobu- tamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure[J].J Am Coll Cardio1,2009,53 (25) :2343 -2348.
  • 8MeCann P, Hauptman PJ. Inotrepie therapy: anim-portantrole in the treatment of advanced symptomatc heart failure[ J]. Med Clin North Am,2012,96 (5) :943-954.
  • 9Omerovic E, Waagste in F, Swedberg K. Is levos men-danbetter than dobuta mine in acyte heart failure in patients on beta-block- ade treament? What is the evidence? [J]. Eur J Heart Fail, 2010,12(4) :313-314.
  • 10Palazzuoli A, Gallotta M, Quatrini I, et al. Natriuretic peptides (BNP and NT-proBNP ):measurement and relevance in heart failure [ J ]. Vas Health Risk Management,2010,6 ( 1 ) :411-418.

引证文献9

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部